Network Insights Methodology Get Access

Merck

ORG Health Care / Pharmaceuticals Momentum 21.0ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. CRITICALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$60B+ revenue (2025), Rahway-based Merck slashed Zepatier pricing on hepatitis C therapy as direct-acting antivirals face generic competition and international access pressure. Move signals pivot toward value-based pricing in specialty infectious disease.

Merck announced steep price cuts for Zepatier (sofosbuvir/velpatasvir/voxilaprevir), its hepatitis C treatment, reflecting competitive pressure in the HCV market and shift toward more affordable access.
0.03
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
21.0
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
7
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Merck is getting less coverage than expected — the market may be ignoring a developing story (primary driver: Attention Cascade).
Connected Entities
Pfizer Novartis PlocamiumAI China FDA AstraZeneca Sanofi India European Union Eli Lilly HHS Robert F. Kennedy Jr. Mumbai Bloomberg Novo Nordisk
Watch This Entity
PSI Intelligence
30-Day Trend
2026-05-10 2026-06-09 10 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.331
Narrative Drift
0.000
Spectral Shift
380.580
Sentiment-Momentum Divergence
0.000
Source Concentration
0.923
Signal
Merck is getting less coverage than expected — the market may be ignoring a developing story (primary driver: Attention Cascade).
Driver
Ranked #5 of 6 in Health Care — in line with sector peers. PSI stable vs yesterday (-1.00). Confidence: 63% (entity has limited history, score is shrunk toward sector prior).
Action
Baseline conditions. Continue standard monitoring cadence.
Peer Comparison
5 of 6
Sector Rank
+0.00
Peer Z-Score
20%
Sector Percentile
Network Analysis
7 Degree Centrality
Ego Network (top connections)
Pfizer (weight 86.0)Novartis (weight 83.0)PlocamiumAI (weight 10.0)China (weight 7.0)FDA (weight 7.0)AstraZeneca (weight 6.0)Sanofi (weight 5.0)India (weight 4.0) PfizerNovartisPlocamiumAIChinaFDAAstraZenecaSanofiIndia Merck (degree 7) Merck
Centrality History
2026-05-10 2026-06-09 10 0 Degree Mentions
EntityWeight StatusFirst Seen
Pfizer 86 STRENGTHENED
Novartis 83 NEW
PlocamiumAI 10 NEW
China 7 STABLE
FDA 7 STABLE
AstraZeneca 6 NEW
Sanofi 5 NEW
India 4 STABLE
European Union 3 STABLE
Eli Lilly 3 NEW
HHS 2 STABLE
Robert F. Kennedy Jr. 2 NEW
Mumbai 2 NEW
Bloomberg 2 STABLE
Novo Nordisk 2 NEW
Dr 1 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-06-09 ← Intelligence Network